Akcea Therapeutics, Inc. (AKCA) Q3 2019 Earnings Call Transcript
AKCA earnings call for the period ending September 30, 2019.
Akcea Therapeutics, Inc.
AKCA
AKCA
$18.77
$0.75
4.2%
BATS BZX Real Time Price as of December 11, 2019, 4:00 p.m. EST
View Interactive AKCA Charts
Akcea Therapeutics, Inc.
News & Analysis: Akcea Therapeutics, Inc.
What Happened in the Stock Market Today
Aksea Therapeutics is teaming up with Pfizer on a new drug, and HEXO got downgraded after the resignation of its CFO.
Here's Why Akcea Therapeutics Jumped 30% Today
A licensing deal gives investors confidence in a turnaround.
Why NIO, Akcea Therapeutics, and Overstock.com Slumped Today
Find out which of these companies investors are the most nervous about.
Akcea Therapeutics, Inc. (AKCA) Q2 2019 Earnings Call Transcript
AKCA earnings call for the period ending June 30, 2019.
Akcea Therapeutics, Inc. (AKCA) Q1 2019 Earnings Call Transcript
AKCA earnings call for the period ending March 31, 2019.
Akcea Therapeutics, Inc. (AKCA) Q4 2018 Earnings Conference Call Transcript
AKCA earnings call for the period ending December 31, 2018.
Here's Why Ionis Pharmaceuticals Rose 12.9% in September
The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.
Can Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. Recover?
A surprise rejection is a major setback for both partners, but not the end of the line.
Here's Why Ionis Pharmaceuticals and Akcea Therapeutics Plummeted Today
The FDA gives a thumbs down to their triglyceride-lowering drug Waylivra.
